FindTrial
Sign In

To study Mucormycosis epidemiology in India

Multicenter observational study on epidemiology, treatment and outcome of Mucormycosis in India

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2016/02/006644
Enrollment
300
Registered
2016-02-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients who diagnosed with Mucormycosis Health Condition 2: B46- Zygomycosis

Interventions

None listed

Sponsors

MYLAN PHARMACEUTICALS PRIVATE LIMITED
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Any age group of patients with confirmed & probable diagnosis of Mucormycosis will be enrolled for this study

Exclusion criteria

Exclusion criteria: Any subject without a confirmed diagnosis of mucormycosis.

Design outcomes

Primary

MeasureTime frame
1.Overall survival at 45 and 90 days 2.Cure: defined as complete resolution of clinical, radiological and mycological evidence 3.Improved: Resolution of clinical features, radiological regression outcome of mucormycosis in IndiaTimepoint: 45 and 90 days—

Secondary

MeasureTime frame
Grade III and IV toxicities of antifungal agentsTimepoint: 45 days—

Countries

India

Contacts

Public ContactDr Atul K Patel

Fungal Infection Study Forum

atulpatel65@gmail.com07926440816

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026